Showing 2061-2070 of 2657 results for "".
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti
- Lars Ederleh Named New CSO at Schwind Eye-Tech-Solutionshttps://modernod.com/news/lars-ederleh-named-new-cso-at-schwind-eye-tech-solutions/2481731/Schwind eye-tech-solutions has named Lars Ederleh as Chief Sales Officer (CSO), effective this month. Bringing more than 20 years of international experience in laser technology, Mr. Ederleh will be in charge of the company’s sales and marketing operations.
- Salvat Laboratories Initiates a Pediatric Study in Europe with SVT-15473 for the Treatment of Inflammation and Pain Following Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-initiates-a-pediatric-study-in-europe-with-svt-15473-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery/2481707/Salvat Laboratories has initiated a new study with SVT-15473 clobetasol to treat inflammation and pain in patients undergoing ocular surgery. The trial will include children aged 0 to 3 years with cataracts, aiming to demonstrate the drug's safety in this population. Cataracts
- Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Trial of ADX‑2191 in Patients with RPhttps://modernod.com/news/aldeyra-therapeutics-announces-improvement-from-baseline-in-retinal-function-in-phase-2-clinical-trial-of-adx2191-in-patients-with-rp/2481703/Aldeyra Therapeutics announced positive topline results from the phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa (RP). Relative to baseline, the clinical trial demonstrated statistically s
- SriniVas R. Sadda, MD, Named 2023-2024 ARVO President Electhttps://modernod.com/news/srinivas-r-sadda-md-named-2023-2024-arvo-president-elect/2481697/Doheny Eye Institute announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 annual meeting in New Orleans. Dr. Sadda has been a member of ARVO for a number of years, and s
- FDA Does Not Approve Regeneron's High-Dose Aflibercepthttps://modernod.com/news/fda-does-not-approve-regenerons-high-dose-aflibercept/2481695/Citing "an ongoing review of inspection findings at a third-party filler," the FDA declined to approve Regeneron's aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).</
- Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patientshttps://modernod.com/news/myra-vision-raises-money-to-advance-calibreye-surgical-treatment-for-glaucoma-patients/2481694/Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product development, scale manufacturing capabilities, and support first-in-human investigation of the company's Calibreye System, a novel treatm
- Luminopia Raises Money to Support Full Commercial Rollout of Amblyopia Therapeutichttps://modernod.com/news/luminopia-raises-money-to-support-full-commercial-rollout-of-amblyopia-therapeutic/2481692/Luminopia announced it has raised an additional $16 million in new capital to support the full commercial rollout later this year of the company’s lead product, Luminopia, a software-based therapeutic for amblyopia, the leading cause of vision loss among children. Luminopia w
- Euclid Announces ABB Optical Group as Licensed Manufacturer and Distributor of Euclid Ortho-K Lenseshttps://modernod.com/news/euclid-announces-abb-optical-group-as-licensed-manufacturer-and-distributor-of-euclid-ortho-k-lenses/2481691/Euclid Vision has announced that ABB Optical Group is now a licensed manufacturer and distributor of the company’s Ortho-K lenses. Financial terms of the deal were not disclosed. ABB, which Euclid says is the largest distributor of soft lenses in the United States,
- Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)https://modernod.com/news/cigna-expands-coverage-of-glaucoma-surgical-procedures-to-include-canaloplasty-and-goniotomy-trabeculotomy/2481686/Cigna has updated its 'Glaucoma Surgical Procedure' policy to cover both ab interno canaloplasty and goniotomy (trabeculotomy) procedures for the treatment of open-angle glaucoma, effective June 15, 2023. “We are pleased that Cigna’s clinical review resulted in